CIK 0001372514
- Non-accelerated filer
- Smaller reporting company
KIORA PHARMACEUTICALS INC
Sign in to watch- Tickers
- KPRX KPHMW
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 980443284
- Phone
- +1 858-224-9600
- Business address
- 169 SAXONY RD., SUITE 212, ENCINITAS, CA, 92024
- Former names
- EYEGATE PHARMACEUTICALS INC
Securities
- KPRX Common Stock Nasdaq
- KPHMW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-01 | CHANEY PAUL G Director | Grant or award · Stock Option (right to buy) | +3,333 | 3,333 | ||
| 2021-02-01 | MALFROY-CAMINE BERNARD Director | Grant or award · Stock Option (right to buy) | +3,333 | 3,333 | ||
| 2021-02-01 | GOLDBERG MORTON Director | Grant or award · Stock Option (right to buy) | +3,333 | 3,333 | ||
| 2021-02-01 | Obermayr Franz Acting CEO | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2021-01-06 | ARMISTICE CAPITAL, LLC Director | Purchase | +1,531,101 | $5.23 | $8.0M | 3,346,601 |
| 2021-01-06 | ARMISTICE CAPITAL, LLC Director | Purchase | +0 | 3,346,601 | ||
| 2021-01-06 | ARMISTICE CAPITAL, LLC Director | Purchase · Warrants | +1,531,101 | 1,531,101 | ||
| 2021-01-06 | ARMISTICE CAPITAL, LLC Director | Purchase · Warrants | +0 | 1,531,101 | ||
| 2021-01-04 | FROM STEPHEN President and CEO | Shares withheld for taxes | −705 | $4.85 | $3K | 77,288 |
| 2021-01-04 | Romano Sarah Chief Financial Officer | Shares withheld for taxes | −115 | $4.85 | $558 | 25,613 |
| 2021-01-04 | MANZO MICHAEL P. VP of Engineering | Shares withheld for taxes | −115 | $4.85 | $558 | 17,292 |
| 2021-01-04 | Mann Brenda VP of Research & Development | Shares withheld for taxes | −115 | $4.85 | $558 | 17,256 |
| 2020-12-07 | Mann Brenda VP of Research & Development | Shares withheld for taxes | −91 | $3.76 | $342 | 17,371 |
| 2020-12-07 | FROM STEPHEN President and CEO | Shares withheld for taxes | −588 | $3.76 | $2K | 77,993 |
| 2020-12-07 | MANZO MICHAEL P. VP of Engineering | Shares withheld for taxes | −91 | $3.76 | $342 | 17,407 |
| 2020-12-07 | Romano Sarah Chief Financial Officer | Shares withheld for taxes | −91 | $3.76 | $342 | 25,728 |
| 2020-11-02 | FROM STEPHEN President and CEO | Shares withheld for taxes | −623 | $3.51 | $2K | 78,581 |
| 2020-11-02 | Mann Brenda VP of Research & Development | Shares withheld for taxes | −96 | $3.51 | $337 | 17,462 |
| 2020-11-02 | Romano Sarah Chief Financial Officer | Shares withheld for taxes | −97 | $3.51 | $340 | 25,819 |
| 2020-11-02 | MANZO MICHAEL P. VP of Engineering | Shares withheld for taxes | −97 | $3.51 | $340 | 17,498 |
Page 9 of 13 · 244 trades